The Top 3 Preclinical Considerations in the Discovery and Development of Novel Oncology Therapeutics
Add bookmark
The Top 3 Preclinical Considerations in the Discovery and Development of Novel Oncology Therapeutics
Add bookmark
In this interview Kenneth J. Olivier Jr., PhD, Director of Toxicology at Merrimack Pharmaceuticals, speaks to Andrea Charles from Pharma IQ, about what trends he is witnessing in the improvement of safety assessments, his top 3 preclinical considerations in the discovery and development of novel oncology therapeutics and the implications and future considerations for use of computational biology in clinical drug development.
[inlinead]
|
|
Have Your Say Rate this feature and give us your feedback in the comments section below |
Tags:
Predictive Toxicology
preclinical considerations
computational biology
clinical drug development
novel oncology therapeutics
Ken Olivier
Merrimack Pharmaceuticals
